Comparative price analysis of biological medicines: disparities generated by different pricing policies

Marcela Amaral Pontes, Alane Andrelino Ribeiro, Flávia Caixeta Albuquerque, Silvana Nair Leite Cotenzini · 2024

Read Comparative price analysis of biological medicines: disparities generated by different pricing policies by Marcela Amaral Pontes, Alane Andrelino Ribeiro, Flávia Caixeta Albuquerque, Silvana Nair Leite Cotenzini (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10808539.txt.

Description

Brazil's pricing rules for biological medicines are compared with other countries' rules by Marcela Amaral Pontes and co-authors, in a study published in 2023. Biological drugs are costly to make, which strains health budgets and limits patient access. Cheaper copycat versions, called biosimilars, should widen access.

Unlike its generic drug policy, Brazil does not require biosimilars to enter at a lower price that reflects their lower development costs. The team compared entry prices and pricing rules across selected countries. They found Brazil's model produced distorted biosimilar prices that are hard for public and private systems to sustain. The distortions, in turn, keep these medicines out of reach for much of the population.

Catalog record

CREATORMarcela Amaral Pontes, Alane Andrelino Ribeiro, Flávia Caixeta Albuquerque, Silvana Nair Leite Cotenzini
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10808539

Browse the full library · About the Tower of Babel